Comparison of clinical safety and effectiveness between urokinase and alteplase in the treatment of cerebral infarction
Objective To analyze the safety and effectiveness between urokinase and alteplase in the treatment of cerebral infarction,and evaluated its clinical value.Methods 100 patients with cerebral infarction were enrolled in this study.They were divided into the control group and the observation group according to random number table,each consisting of 50 patients.The control group was treated with urokinase,and the observation group was treated with alteplase.The degree of neurologic deficit,clinical indicators,clinical therapeutic effect and incidence of adverse reactions were compared between the two groups.Results The National Institutes of Health Stroke Scale(NIHSS)scores of the observation group were(21.26±0.38),(14.26±0.88)and(10.28±0.68)points at 2 h,1 d and 7 d after treatment,which were lower than(23.22±0.71),(17.74±0.91)and(14.35±0.71)points in the control group,and the difference was significant(P<0.05).The hospitalization time of(22.61±1.38)d in the observation group was longer than(17.53±1.62)d in the control group,and the treatment cost of(14350.26±128.38)yuan was higher than(11273.22±124.52)yuan in the control group.The difference was significant(P<0.05).The total effective rate of the observation group was 96.00%,which was significantly higher than 82.00%of the control group,and the difference was significant(P<0.05).The incidence of adverse reactions in the observation group was 2.00%,which was significantly lower than 14.00%in the control group,and the difference was significant(P<0.05).Conclusion During the treatment of cerebral infarction,the clinical effectiveness and safety of alteplase are higher than that of urokinase.Although the effect is ideal,the treatment cost is relatively high and the treatment cycle is relatively long.Therefore,it is necessary to select drugs reasonably according to the actual situation of patients with cerebral infarction.
万方数据
维普
